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The role of behavioural science in changing deprescribing practice 
 
Over 50% of older people are prescribed a medicine with more harm than benefit leading to 
avoidable morbidity, hospitalisation and mortality(1). The World Health Organisation has recognised 
this problem in its recent Global Patient Safety Challenge: Medication Without Harm. Deprescribing 
is the process of identifying and discontinuing medicines that are no longer appropriate. The term 
deprescribing is a relative newcomer to the research and clinical vocabulary. Medicines may be 
deprescribed for several reasons including when they are no longer indicated, when the harms 
outweigh the benefits or when treatment may not align with the patient’s healthcare goals and 
treatment preferences. Whilst the principle of deprescribing has always been an expectation of good 
prescribing practice, there are numerous barriers to it becoming routine that are discussed in section 
3(2,3). 
Deprescribing involves establishing an accurate account of the patient’s prescribed medicines, 
identifying medicines that are appropriate for deprescribing, achieving agreement with the patient 
to attempt deprescribing and ensuring monitoring and appropriate safety netting are in place. It 
therefore requires practitioner and patient behaviours to align as they collaboratively navigate the 
process. Despite global traction towards developing strategies to support practitioners and patients 
to deprescribe, there have been only marginal successes in effecting change in deprescribing 
behaviour(4). 
The three key unknowns to designing interventions to change behaviour are: 1. defining the target 
behaviour; 2. specifying whose behaviour needs to change and 3. identifying how to achieve the 
desired change(3). The field of behavioural science applies theory and empirical evidence to address 
these three unknowns. 
 
1. Defining the target behaviour 
We have often fallen at the first hurdle when defining the target behaviour in deprescribing; some 
define it as stopping medicines to prevent harm, others consider it to be stopping medicines in 
response to harm and some fail to make any distinction. The terms ‘reactive deprescribing’ and 
‘proactive deprescribing’ emerged in 2018 to define these two distinct behaviours(5). Reactive 
deprescribing is “discontinuing a medicine in response to an adverse clinical trigger”. Proactive 
deprescribing is “discontinuing a medicine if future gains are unlikely to outweigh future harms”. The 
barriers and enablers to each behaviour differ substantially. Practitioner motivation to reactively 
deprescribe is likely to be very high given that failure to undertake the behaviour leads to certain 
patient harm(2). For example, reactively deprescribing anticoagulant for a patient presenting with a 
gastric bleed. Motivation to proactively deprescribe, however, may be hampered by the 
uncertainties regarding the likely benefits and potential harms(3). For example, a practitioner may 
be reticent to proactively deprescribe an antihypertensive for a patient even if the risk of falling and 
resulting fracture is greater than the risk of a cardiovascular event. This difference is reflected in 
practice with 80% of all medicines deprescribed in hospital being reactive. The 20% of proactive 
deprescribing cases all had documented evidence of no clinical benefit thus only potential for harm, 
rather than a complex evaluation of risks and benefits. Proactive deprescribing is therefore the 
behaviour that requires targeting to reduce avoidable medication-related harm. 
 
2. Specifying whose behaviour needs to change 
Both practitioner and patient behaviour are key to successful proactive deprescribing and 
interventions targeting both have been developed. However, patient behaviour change 
interventions have only been reported for medicines where guidelines specify that continued 
prescribing is inappropriate such as the EMPOWER brochure. This provides patients with information 
regarding the risks of benzodiazepines which guidelines state should not be continued long-term for 
the management of insomnia. The EMPOWER brochure encourages patients to initiate deprescribing 
conversations with healthcare practitioners. It was tested in a randomised controlled trial with 
community-dwelling individuals and demonstrated that 27% of patients had a benzodiazepine 
deprescribed at six months, which was 22% greater than the control(7). For medicines with less 
clarity regarding when to deprescribe, patients and carers want these deprescribing discussions to 
be initiated by the prescriber(6). Over 80% of patients and carers indicate they would be willing to 
have a medicine deprescribing if this was recommended by their prescriber(6). 
There is a growing body of literature to support practitioners in screening medicines for potential 
deprescribing such as Beers and STOPP, and guidelines directing how to safely discontinue medicines 
have also been developed(8). However, a systematic review of randomised controlled trials of 
practitioner focussed deprescribing interventions comprising primarily screening tools alone, 
resulted in a mean effect size of less than one medicine deprescribed(4) indicating that addressing 
knowledge and skills alone is insufficient. Moving forward, the focus should therefore be on 
developing practitioner behaviour change interventions that incorporate the other components to 
address the remaining barriers and enablers. These interventions should support practitioners to 
work with patients to facilitate shared deprescribing decision-making. 
 
3. Identifying how to achieve the desired change 
Behaviour change interventions should address the barriers and enablers (determinants) from the 
perspective of the person whose behaviour requires changing(9). Behaviour change theory provides 
the lens through which these determinants can be conceptualised and appropriate behaviour 
change techniques (BCTs) selected. BCTs are the ‘active ingredients’ of interventions that address 
the determinants to bring about the required change in behaviour(9).  
The determinants of deprescribing from the primary care practitioner perspective were reported in a 
2014 systematic review(2). Limited skills, knowledge and perceived patient resistance to 
deprescribing are key barriers, whereas access to specialists in deprescribing such as geriatricians 
and pharmacists for advice is an enabler. Clinical guidelines are also heavy influencers of prescribing 
practice, and the current overrepresentation of single-disease guidelines that focus solely on 
prescribing rather than deprescribing are a barrier(2,3). 
Application of behaviour change theory to develop proactive deprescribing interventions to address 
the determinants in primary care is yet to be reported(2).The hospital deprescribing implementation 
framework (hDIF) provides the five key determinants to proactive deprescribing in hospital and 44 
BCTs for addressing these determinants(3). The hDIF affords the flexibility of each of the five 
determinants being linked to between five and 17 BCTs. This enables organisations to select from 
these BCTs according to individual context such as organisational resources. This flexibility offered by 
the hDIF aligns the new way of working with the target audience, gains trust and promotes 
ownership(3). Selection of BCTs from the hDIF in partnership with the target audience of 
geriatricians and pharmacists was recently reported for the UK hospital context. Selected BCTs 
include organisational action planning to raise the priority of deprescribing in hospitals, restructuring 
pharmacists’ working patterns to enable them to attend multidisciplinary team meetings and 
measuring, reporting and sharing of deprescribing activity between teams to incentivise the 
activity(10).A programme of work to test the intervention is now underway to determine 
effectiveness and cost-effectiveness in changing practitioner proactive deprescribing behaviour. 
As the body of trial evidence testing practitioner deprescribing behaviour change interventions 
builds, there comes a need to develop and validate measures of success. The extent to which the 
intervention leads to the desired behaviour change as measured by the number of medicines 
deprescribed determines efficacy. Whilst this is clearly an important process measure, patient and 
health system orientated measures are necessary for informing policy and commissioning decisions.  
Core outcome sets standardise the outcomes that should be measured and reported for the specific 
area of health under investigation. There is currently no core outcome set for trials of practitioner 
deprescribing interventions. Cost and quality of life are central to most medication related core 
outcome sets and are likely to be incorporated into a deprescribing core outcome set. Additionally, 
the patient experience of the care delivered by the practitioner is also an important component of 
most core outcome sets. Whilst the practitioner is the recipient of the behaviour change 
intervention, the patient is the recipient of the resulting practitioner behaviour. A key measure of 
success is therefore a positive patient experience. For example, this may culminate in patients 
feeling that medicines have been comprehensively reviewed by the prescribed, that they have been 
adequately supported to make shared decisions and that they have confidence in the ongoing 
monitoring strategy. Developing and validating a tool to capture the patient experience will 
therefore serve to both evaluate and inform necessary refinements of the intervention.  
 
Conclusion 
Proactive deprescribing is an essential weapon in our armoury against inappropriate medication use. 
However, it is a well-recognised deficit in clinical practice. Patients want practitioners to initiate the 
process, yet over a decade of research endeavour has been divided between practitioner and 
patient behaviour change. This may explain the marginal progress in achieving the required 
practitioner behaviour change. The boom in deprescribing research is therefore here to stay with an 
additional focus on practitioner behaviour change to complement ongoing patient behaviour change 
research. Capturing the patient experience should also become a central component in the 
evaluation of these deprescribing behaviour change interventions. 
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